|
CMEA Capital is a venture capital firm located in San Francisco, California. The firm was founded by Tom Baruch with New Enterprises Associates in 1989 as a $40M fund entitled “Chemical and Materials Enterprise Associates”. ==History== CMEA’s early focus was on investing in startup enterprises that commercialized new applications of specialty chemicals and materials technologies. Twenty-one years later, CMEA Capital has raised six additional funds and currently has $1.1 billion under management. CMEA Capital provides capital to entrepreneurs in the energy and materials, information technology, and life science sectors. The company has been an investor in more than 120 energy & materials, information technology and life sciences companies over the past twenty one years including: Aclara Biosciences (which merged with Monogram Biosciences, Biomimetic Therapeutics, Cadabra Design Automation (acquired by Synopsys〔(【引用サイトリンク】title= Cadabra Automates the Creation of Standard Cell Layouts )〕), Everest Design Automation (acquired by Synopsys〔(【引用サイトリンク】title= Synopsys Acquires Everest Design Automation )〕). Tom Baurch retired from the firm in 2010. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「CMEA Capital」の詳細全文を読む スポンサード リンク
|